Dermata Therapeutics Inc (DRMA)

Jun 11, 2026

Dermata Therapeutics Warrant (DRMAW) Slides 19.73% as Price Nears Critical Floor at $0.01Dark Pool Volume - newsline.com

Jun 11, 2026

Jun 08, 2026

DRMA Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Control Amid Pipeline ProgressQuarterly Financial Update - newsline.com

Jun 08, 2026

Jun 06, 2026

DRMA Q1 2026 Earnings: Better-than-Expected Loss Reduction Amidst Pipeline Development FocusShare Dilution Risk - newsline.com

Jun 06, 2026

Jun 06, 2026

DRMA Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Advances ContinueSlow Growth Warning - newsline.com

Jun 06, 2026

Jun 04, 2026

Dermata Therapeutics (DRMA) Edges Higher as Stock Tests Key Resistance LevelsVolume Climax - newsline.com

Jun 04, 2026

Jun 03, 2026

Lixte Biotechnology Holdings, Inc. (LIXTW) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jun 03, 2026

Jun 02, 2026

DRMA Q1 2026 Earnings: Positive EPS Surprise as Dermata Advances PipelinePreliminary Results - newsline.com

Jun 02, 2026

Jun 01, 2026

CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D - Stock Titan

Jun 01, 2026

Jun 01, 2026

[EFFECT] Dermata Therapeutics, Inc. SEC Filing - Stock Titan

Jun 01, 2026

May 31, 2026

Dermata Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView

May 31, 2026

May 31, 2026

Dermata Therapeutics Warrant (DRMAW) Holds at Penny Level – Key Levels to WatchAI Trade Signals - newsline.com

May 31, 2026

May 29, 2026

Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf registration - Stock Titan

May 29, 2026

May 28, 2026

Dermata Therapeutics (DRMA) Stages Modest Recovery – Support Holds Above $1.28Keltner Channel - The Legal Advocate

May 28, 2026

May 28, 2026

Dermata Therapeutics (DRMA) Shares Climb 3.85% as Stock Tests Key Resistance LevelsVolume Breakout Ideas - The Legal Advocate

May 28, 2026

May 28, 2026

Dermata Therapeutics Adopts Fourth Amendment to 2021 Omnibus Equity Incentive Plan – Form 8-K Filing Summary - Minichart

May 28, 2026

May 27, 2026

Dermata Therapeutics Shareholders Approve Equity Plan and Directors - TipRanks

May 27, 2026

May 27, 2026

Dermata (NASDAQ: DRMA) investors approve equity plan expansion and warrant changes - Stock Titan

May 27, 2026

May 26, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

May 26, 2026

May 23, 2026

DRMA Q1 2026 Earnings: Narrower Loss Than Expected Bolsters Investor SentimentRevenue Report - Newser

May 23, 2026

May 22, 2026

Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf for stock, warrants - Stock Titan

May 22, 2026

May 22, 2026

DRMA Q1 2026 Earnings: Narrower-than-Expected Loss Marks Progress for Clinical-Stage BiotechEarnings Yield Spread - The Legal Advocate

May 22, 2026

May 21, 2026

Dermata Therapeutics (DRMA) Slides 0.8% as Shares Hover Near Support at $1.18Virgin POC - Newser

May 21, 2026

May 21, 2026

Dermata Therapeutics Warrant (DRMAW) Holds at $0.01 as Trading Remains FlatGap Fill Strategy - Newser

May 21, 2026

May 17, 2026

Dermata shares rise after USPTO issues patent notice of allowance - MSN

May 17, 2026

May 15, 2026

Dermata Therapeutics, Inc.Common Stock (NQ: DRMA - FinancialContent

May 15, 2026

May 15, 2026

DRMA Should I Buy - Intellectia AI

May 15, 2026

May 14, 2026

Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent

May 14, 2026

May 14, 2026

DRMA Stock Chart | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill

May 14, 2026

May 13, 2026

DRMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

May 13, 2026

May 13, 2026

Dermata Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2026

May 13, 2026

Dermata Therapeutics (NASDAQ:DRMA) Q1 2026 Earnings: Narrowing Losses and Strategic Pivot to DTC Skincare - ChartMill

May 13, 2026

May 13, 2026

Intracoastal-linked holders report 4.99% stake in Dermata (NASDAQ: DRMA) - Stock Titan

May 13, 2026

May 13, 2026

Once-weekly Tome mask aims to bring professional skincare home by mid-2026 - Stock Titan

May 13, 2026

May 13, 2026

[10-Q] Dermata Therapeutics, Inc. Quarterly Earnings Report - Stock Titan

May 13, 2026

May 13, 2026

Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 13, 2026

May 13, 2026

Dermata (NASDAQ: DRMA) advances DTC pivot in Q1 2026 update - Stock Titan

May 13, 2026

May 13, 2026

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 - newswire.com

May 13, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 11, 2026

What Dermata (DRMAW) flagged as biggest challenges ahead | DRMAW Q3 Earnings: Dermata Warrant Reports No Revenue or Earnings DataCommunity Sell Signals - Newser

May 11, 2026

May 08, 2026

Dermata Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView

May 08, 2026

May 06, 2026

Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

May 06, 2026

May 03, 2026

DRMAW Dermata quarterly earnings core metrics remain unavailable as investors await full official operational and financial disclosures.Forward Guidance - newser.com

May 03, 2026

May 02, 2026

DRMAW SEC FilingsDermata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

May 02, 2026

Apr 23, 2026

RBC Capital initiates Dermata Therapeutics stock at outperform By Investing.com - Investing.com South Africa

Apr 23, 2026

Apr 23, 2026

RBC Capital initiates Dermata Therapeutics stock at outperform - Investing.com

Apr 23, 2026

Apr 22, 2026

Dermata (DRMA) Stock Valuation | Dermata Therapeutics posts narrower loss, 3.2 pct EPS beatSurprise Factor - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 22, 2026

Bigger Capital now holds 75,200 shares after sales (NASDAQ: DRMA) - Stock Titan

Apr 22, 2026

Apr 20, 2026

Dermata (DRMA) Stock Hot Topic (Institutional Selling) 2026-04-20Analyst Consensus - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 17, 2026

Dermata Therapeutics (NASDAQ: DRMA) seeks approval for warrants and equity plan at 2026 meeting - Stock Titan

Apr 17, 2026